首页|拉氧头孢治疗大叶性肺炎的疗效及预后分析

拉氧头孢治疗大叶性肺炎的疗效及预后分析

扫码查看
目的 探讨拉氧头孢对大叶性肺炎的治疗效果及对患者预后的影响.方法 选取苍南县人民医院2015年12月~2017年5月收治的90例大叶性肺炎患者,随机数字表法均分为研究组和对照组,每组45例.研究组在常规治疗基础上加用拉氧头孢,对照组在常规治疗基础上加用头孢哌酮,记录并比较2组治疗2 w后临床疗效、药物相关不良反应发生情况.结果 研究组大叶性肺炎患者临床总有效率(93.33%)显著高于对照组(73.33%)(P<0.05);治疗期间2组药物相关不良反应发生率对比差异无统计学意义.结论 应用拉氧头孢治疗大叶性肺炎可显著提高患者临床疗效,有利于保障其预后及生活质量.
Effect and prognosis of treatment of lobar pneumonia with latamoxet
Objective To investigate the therapeutic effect of cefradine on lobar pneumonia and its influence on the prognosis of patients with lobar pneumonia. Methods 90 cases of lobar pneumonia patients from December 2015 to May 2017 were randomly divided into the study group and the control group, with 45 cases in each group. The study group was treated with latamoxef on the basis of routine treatment, the control group was treated with cefoperazone on the basis of routine treatment ,recorded in two groups after 2 weeks of treatment. The clinical efficacy,drug related adverse reactions occur of the two groups were recorded after two weeks of treatment. Results The total effective rate in the study group(93.33%) was significantly higher than that of the control group(73.33%)(P<0.05). There was no significant difference in the incidence of drug-related adverse reactions between the two groups during the treatment period. Conclusion The application of latamoxet in the treatment of lobar pneumonia can significantly improve the clinical efficacy of patients, and is conducive to the protection of their prognosis and quality of life.

lobar pneumonialatamoxef clinical efficacyprognosis

陈尔阳、魏昌泵

展开 >

苍南县人民医院 药剂科,浙江 温州 325800

大叶性肺炎 拉氧头孢 临床疗效 预后

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(10)
  • 4